CN116143704A - 司来帕格体内代谢物的一氧化氮供体药物 - Google Patents
司来帕格体内代谢物的一氧化氮供体药物 Download PDFInfo
- Publication number
- CN116143704A CN116143704A CN202310167400.0A CN202310167400A CN116143704A CN 116143704 A CN116143704 A CN 116143704A CN 202310167400 A CN202310167400 A CN 202310167400A CN 116143704 A CN116143704 A CN 116143704A
- Authority
- CN
- China
- Prior art keywords
- alkylene
- nitric oxide
- pharmaceutical composition
- oxide donor
- selexipag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims abstract description 29
- 238000001727 in vivo Methods 0.000 title claims abstract description 22
- 239000002840 nitric oxide donor Substances 0.000 title claims abstract description 16
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical class C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 title abstract description 26
- 239000002207 metabolite Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 102000009079 Epoprostenol Receptors Human genes 0.000 claims description 8
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- -1 hydroxy, carboxyl Chemical group 0.000 claims description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 6
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000000018 receptor agonist Substances 0.000 claims description 5
- 229940044601 receptor agonist Drugs 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229960002414 ambrisentan Drugs 0.000 claims description 3
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims description 3
- 229960003065 bosentan Drugs 0.000 claims description 3
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical group COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229960003310 sildenafil Drugs 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims 1
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 229940023488 pill Drugs 0.000 claims 1
- 229960003841 selexipag Drugs 0.000 abstract description 17
- 208000002815 pulmonary hypertension Diseases 0.000 abstract description 10
- 210000002460 smooth muscle Anatomy 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 102000015433 Prostaglandin Receptors Human genes 0.000 abstract description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 abstract description 3
- 230000002040 relaxant effect Effects 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 238000001308 synthesis method Methods 0.000 description 19
- 210000001147 pulmonary artery Anatomy 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229960001123 epoprostenol Drugs 0.000 description 6
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940127314 Prostacyclin Receptor Agonists Drugs 0.000 description 2
- 206010039163 Right ventricular failure Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- JEBDAQCJIFFAFF-UHFFFAOYSA-N 2-bromoethyl nitrate Chemical compound [O-][N+](=O)OCCBr JEBDAQCJIFFAFF-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033433 Pain in jaw Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000010417 nitric oxide pathway Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种如式I所示的司来帕格体内代谢物的一氧化氮供体药物，
所述药物可以与前列素受体特异性结合，发挥舒张血管平滑肌，治疗肺动脉高压的作用。所述药物进一步提高了司来帕格体内代谢物的生物利用度，改善了其药代动力学，可以减少给药的剂量和服用频率，提高药物的有效性和安全性。
Description
技术领域
本发明属于医药技术领域，涉及一种治疗肺动脉高压的药物，具体涉及一种司来帕格体内代谢物的一氧化氮供体药物及其应用。
背景技术
肺动脉高压(pulmonary arterial hypertension，PAH)是一类肺动脉压力和肺血管阻力进行性升高，最终可致右心功能衰竭和患者死亡的恶性心血管系统疾病，预后极差。肺动脉高压的发病机制尚未完全明确，目前认为肺血管的收缩与舒张失衡、原位血栓形成、内皮和平滑肌的异常增殖、炎性反应以及肺小动脉的重构在其中起着重要作用。目前PAH的靶向药物有三条途径，即一氧化氮途径、内皮素途径及前列环素途径，主要通过改善肺动脉的异常收缩、抑制肺动脉平滑肌细胞增殖等达到治疗作用。国内常用的前列环素途径药物包括曲前列尼尔和司来帕格，其中司来帕格是一种口服的高选择性前列环素(prostacyclin，IP)受体激动剂，其口服给药方式大大提高了患者的依从性。
司来帕格是第一种获得批准的靶向于前列环素途径的口服非前列环素类前列环素受体激动剂。司来帕格与其主要活性代谢产物MRE-269均能高度选择性地与前列环素受体结合，进而产生扩张血管、抗血管平滑肌细胞增殖和抗血管纤维化的作用。体外实验显示，司来帕格的活性代谢产物MRE-269激动前列环素受体的作用较司来帕格强约37倍。即使在司来帕格的血药浓度达到稳态后，MRE-269的前列环素受体激动作用仍较司来帕格强3～4倍。因此，目前认为MRE-269是司来帕格药理作用的主要贡献者。
司来帕格治疗的不良反应主要为头痛、腹泻、恶心、下颌疼痛、呕吐、呼吸困难、肌痛和脸红等，且不良反应呈剂量依赖性。因此，进一步提高司来帕格体内代谢物的生物利用度，改善其药代动力学，提高药物的有效性和安全性是本领域技术人员亟待解决的问题。
发明内容
本发明针对现有技术存在的问题，提供了一种司来帕格体内代谢物的一氧化氮供体药物，发挥靶向前列素受体和调控NO作用，所述药物可用于肺动脉高压的治疗，进一步提高了司来帕格体内代谢物的生物利用度，改善了其药代动力学，可以减少给药的剂量和服用频率，提高药物的有效性和安全性。
为实现上述目的，本发明采用的技术方案如下：
本发明第一个方面提供了一种司来帕格体内代谢物的一氧化氮供体药物，其结构如式I所示：
其中，n为0，1，2，3或4；
R为-X-ONO2、-OC(O)-X-ONO2、-O-X-ONO2、或
其中X为直链或支链的C1-C10亚烷基、C3-7环亚烷基、C6-10芳基、C6-10芳基-C1-C10亚烷基或C1-C10亚烷基-C6-10芳基-C1-C10亚烷基；其中C1-C10亚烷基、C3-7环亚烷基或C6-10芳基可被以下一个或者多个取代基取代：卤原子、羟基、羧基、氰基或-(C1-C10亚烷基)-ONO2。
在一些实施方式中，X为直链或支链的C1-C6亚烷基、C4-6环亚烷基、苯基、苯基-C1-C6亚烷基或C1-C6亚烷基-苯基-C1-C6亚烷基；其中C1-C6亚烷基、C4-6环亚烷基或苯基可被以下一个或者多个取代基取代：卤原子、羟基、羧基、氰基或-(C1-C6亚烷基)-ONO2。
本发明第二个方面提供了一种药物组合物，包含本发明的司来帕格体内代谢物的一氧化氮供体药物及药学上可接受的辅料。
在一些实施方案中，所述药物组合物还包含附加治疗剂，所述附加治疗剂为适用于治疗肺动脉高压的药物，包括但不限于波生坦、安立生坦、西地那非等。
本发明第三个方面提供了所述司来帕格体内代谢物的一氧化氮供体药物或所述药物组合物在制备治疗肺动脉高压的药物中的应用。
本发明第四个方面提供了所述司来帕格体内代谢物的一氧化氮供体药物在制备前列环素受体激动剂中的应用。
相对于现有技术，本发明具有以下有益效果：
本发明提供的一系列司来帕格体内代谢物的NO供体药物，可以与前列素受体特异性结合，发挥舒张血管平滑肌、治疗肺动脉高压的作用。进一步提高了司来帕格体内代谢物的生物利用度，改善了其药代动力学，可以减少给药的剂量和服用频率，提高药物的有效性和安全性。
附图说明
图1为低氧性肺动脉高压大鼠体内试验结果。
具体实施方式
定义和一般术语
除非另有说明，本发明的术语采用以下定义：
术语“亚烷基”是指从直链或支链饱和碳氢化合物消去两个氢原子得到的饱和二价烃基。亚烷基基团的实例包括但并不限于，亚甲基(-CH2-)、亚乙基(-CH2CH2)、亚丙基(-CH2CH2CH2-)、次乙基(-CH(CH3)-)、次异丙基(-CH(CH3)CH2-)等等。
术语“环亚烷基”是指从3到7元饱和烃环上消去两个氢原子得到的饱和二价环烷烃基。环亚烷基的实例包括但不限于
等。
术语“卤原子”是指F、Cl、Br或I。
术语“取代”是指所给结构中的一个或多个氢原子被具体取代基所取代，当所给出的结构式中不只一个位置能被选自具体基团的一个或多个取代基所取代，那么取代基可以相同或不同地在各个位置取代。
术语“体内代谢物”是指具体的化合物或其盐在体内通过代谢作用所得到的产物。
术语“生物利用度”是指本文所公开的化合物被递送到所研究的动物或人的全身循环中的重量百分比。当静脉内施用时，药物的总暴露量(AUC(0-∞))通常被定义为100％生物利用度(F％)。“口服生物利用度”是指与静脉内注射相比，当口服药物组合物时，本文所公开的化合物被吸收到全身循环中的程度。
化合物
本发明涉及一种如式I所示的司来帕格体内代谢物的一氧化氮供体药物：
其中，n为0，1，2，3或4；
R为-X-ONO2、-OC(O)-X-ONO2、-O-X-ONO2、或
其中X为直链或支链的C1-C10亚烷基、C3-7环亚烷基、C6-10芳基、C6-10芳基-C1-C10亚烷基或C1-C10亚烷基-C6-10芳基-C1-C10亚烷基；其中C1-C10亚烷基、C3-7环亚烷基或C6-10芳基可被以下一个或者多个取代基取代：卤原子、羟基、羧基、氰基或-(C1-C10亚烷基)-ONO2。
在一些实施方式中，X为直链或支链的C1-C6亚烷基、C4-6环亚烷基、苯基、苯基-C1-C6亚烷基或C1-C6亚烷基-苯基-C1-C6亚烷基；其中C1-C6亚烷基、C4-6环亚烷基或苯基可被以下一个或者多个取代基取代：卤原子、羟基、羧基、氰基或-(C1-C6亚烷基)-ONO2。
本发明所述的式I结构的化合物包括但不限于以下具体化合物：
组合物
本发明的药物组合物包括式I的化合物和药学上可接受的辅料。
所述的药用辅料可为药物生产领域中广泛采用的那些辅料。辅料主要用于提供一个安全、稳定和功能性的药物组合物，还可以提供方法，使受试者接受给药后活性成分以所期望速率溶出，或促进受试者接受组合物给药后活性成分得到有效吸收。所述的药用辅料可以是惰性填充剂，或者提供某种功能，例如稳定该组合物的整体pH值或防止组合物活性成分的降解。所述的药用辅料可以包括下列辅料中的一种或多种：粘合剂、助悬剂、乳化剂、稀释剂、填充剂、成粒剂、胶粘剂、崩解剂、润滑剂、抗粘着剂、助流剂、润湿剂、胶凝剂、吸收延迟剂、溶解抑制剂、增强剂、吸附剂、缓冲剂、螯合剂、防腐剂、着色剂、矫味剂和甜味剂。
在一些实施方式中，本发明涉及的药物组合物，进一步包含附加治疗剂。所述附加治疗剂为适用于治疗肺动脉高压的药物，包括但不限于波生坦、安立生坦、西地那非等。
在一些实施方式中，本发明涉及的药物组合物为任何可接受的口服剂型，包括但并不限于片剂、胶囊剂、囊片剂、丸剂、含片剂、粉剂、糖浆剂、酏剂、混悬剂、溶液剂、乳剂、颗粒剂或扁囊剂等剂型。
本发明的药物组合物可根据公开的内容使用本领域技术人员已知的任何方法来制备。例如，常规混合、溶解、造粒、乳化、磨细、包封、包埋或冻干工艺。
化合物和组合物的用途
本发明的化合物或药物组合物可用于制备治疗肺动脉高压的药物，或用于制备前列环素受体激动剂。
肺动脉高压是以肺小动脉的血管痉挛、内膜增生和重构为主要特征的一种病理现象，发展到后期可引起右心功能衰竭，直至死亡。在静息状态下，通过右心导管测得平均肺动脉压(mPAP)≥25mmHg，肺动脉楔压(PAWP)≤15mmHg，即可诊断肺动脉高压。
前列环素受体激动剂可增加前列环素的浓度，进而扩张肺动脉平滑肌，抑制平滑肌增生和抑制血小板聚集，改善右心功能和血流动力学。
本发明的化合物或组合物可作为前列环素受体激动剂，与前列环素受体特异性结合，发挥舒张血管平滑肌，治疗肺动脉高压的作用。
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。另外，值得说明的是，本发明所涉及的原料如无特殊说明均为普通市售产品。
实施例1
合成路线：
实施例1的合成
将司来帕格体内活性化合物MRE-269(参考专利CN201911267969.4制得)(84mg)，用2mL无水DMF溶解，将碘化钾(52mg)、碳酸钾(50mg)和2-溴乙基硝酸酯(70mg)的二氯甲烷溶液滴入，移至50℃条件下搅拌反应2h，TLC检测反应完全，旋干溶剂，HPLC纯化得化合物1，收率66％。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.68(ddt,J＝14.6,6.2,1.5Hz,4H),7.57–7.43(m,4H),7.43–7.30(m,2H),4.67(t,J＝6.2Hz,2H),4.46(t,J＝6.1Hz,2H),4.01(s,2H),3.84(hept,J＝6.5Hz,1H),3.70(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.92–1.62(m,4H),1.32(d,J＝6.6Hz,6H).
实施例2
参考实施例1的合成方法，可制得化合物2。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.68(ddt,J＝14.6,6.2,1.5Hz,4H),7.56–7.43(m,4H),7.43–7.17(m,2H),4.41(t,J＝6.0Hz,2H),4.29(t,J＝6.1Hz,2H),4.12(s,2H),3.84(hept,J＝6.5Hz,1H),3.70(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),2.13(p,J＝6.2Hz,2H),1.87–1.63(m,4H),1.32(d,J＝6.6Hz,6H).
实施例3
参考实施例1的合成方法，可制得化合物3。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.68(ddt,J＝15.2,6.2,1.5Hz,4H),7.58–7.43(m,4H),7.43–7.27(m,2H),4.48–4.25(m,2H),4.24–4.03(m,4H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.46(t,J＝6.0Hz,2H),2.01–1.59(m,8H),1.31(d,J＝6.5Hz,6H).
实施例4
参考实施例1的合成方法，可制得化合物4。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝11.7,6.2,1.5Hz,4H),7.48(ddt,J＝7.8,6.4,1.8Hz,4H),7.44–7.31(m,2H),4.27(t,J＝6.0Hz,2H),4.16–4.03(m,4H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.86–1.64(m,8H),1.64–1.51(m,2H),1.32(d,J＝6.6Hz,6H).
实施例5
参考实施例1的合成方法，可制得化合物5。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝8.0,6.1,1.4Hz,4H),7.53–7.43(m,6H),7.43–7.29(m,4H),5.41(t,J＝1.0Hz,2H),5.18(t,J＝0.9Hz,2H),4.09(s,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.93–1.63(m,4H),1.33(d,J＝6.6Hz,6H).
实施例6
参考实施例1的合成方法，可制得化合物6。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝8.0,6.1,1.4Hz,4H),7.57–7.44(m,4H),7.44–7.27(m,4H),7.15–6.91(m,2H),5.42(t,J＝1.0Hz,2H),4.25(t,J＝6.4Hz,2H),4.20–4.00(m,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝5.9Hz,2H),2.89(tt,J＝6.5,1.0Hz,2H),1.87–1.64(m,4H),1.33(d,J＝6.6Hz,6H).
实施例7
参考实施例1的合成方法，可制得化合物7。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.68(ddt,J＝15.2,6.2,1.5Hz,4H),7.58–7.41(m,4H),7.41–7.26(m,2H),4.84(p,J＝5.5Hz,1H),4.41(dd,J＝5.5,1.1Hz,2H),4.01(q,J＝15.2Hz,2H),3.84(hept,J＝6.5Hz,1H),3.76–3.59(m,2H),3.56–3.37(m,2H),1.96–1.61(m,6H),1.32(dd,J＝25.0,6.5Hz,6H),0.98(t,J＝7.4Hz,3H).
实施例8
参考实施例1的合成方法，可制得化合物8。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.77–7.59(m,4H),7.48(ddt,J＝7.8,6.4,1.7Hz,4H),7.42–7.24(m,2H),4.40–4.21(m,2H),4.21–4.00(m,4H),3.84(hept,J＝6.5Hz,1H),3.78–3.61(m,2H),3.47(t,J＝6.0Hz,2H),2.01–1.84(m,3H),1.84–1.63(m,4H),1.53(qdd,J＝7.5,6.2,3.2Hz,2H),1.32(dd,J＝25.0,6.5Hz,6H),0.91(t,J＝7.3Hz,3H).
实施例9
参考实施例1的合成方法，可制得化合物9。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝8.0,6.1,1.4Hz,4H),7.59–7.42(m,4H),7.42–7.27(m,2H),4.63(p,J＝5.5Hz,1H),4.10(s,2H),4.04(d,J＝6.2Hz,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.95–1.58(m,13H),1.32(d,J＝6.6Hz,6H).
实施例10
参考实施例1的合成方法，可制得化合物10。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝11.6,6.2,1.5Hz,4H),7.48(ddt,J＝7.8,6.5,1.8Hz,4H),7.44–7.30(m,2H),4.93(p,J＝6.3Hz,1H),4.14(s,2H),4.03(d,J＝6.1Hz,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.46(t,J＝6.0Hz,2H),2.23–1.99(m,5H),1.92–1.64(m,4H),1.32(d,J＝6.6Hz,6H).
实施例11
参考实施例1的合成方法，可制得化合物11。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.68(ddt,J＝15.2,6.2,1.5Hz,4H),7.57–7.42(m,4H),7.42–7.29(m,2H),5.13(s,2H),4.62(t,J＝6.2Hz,2H),4.08(s,2H),3.86(dt,J＝13.8,6.4Hz,3H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.89–1.64(m,4H),1.32(d,J＝6.6Hz,6H).
实施例12
参考实施例1的合成方法，可制得化合物12。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝11.6,6.2,1.5Hz,4H),7.56–7.43(m,4H),7.43–7.30(m,2H),4.57(t,J＝6.2Hz,2H),4.31(t,J＝6.2Hz,2H),4.02(s,2H),3.93–3.76(m,3H),3.70(dt,J＝23.1,6.2Hz,4H),3.47(t,J＝6.0Hz,2H),1.88–1.63(m,4H),1.32(d,J＝6.6Hz,6H).
实施例13
参考实施例1的合成方法，可制得化合物13。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.77–7.59(m,4H),7.58–7.42(m,4H),7.42–7.26(m,2H),4.57(t,J＝6.2Hz,2H),4.17(t,J＝6.1Hz,2H),4.10(s,2H),3.84(hept,J＝6.5Hz,1H),3.76(t,J＝6.2Hz,2H),3.68(t,J＝6.3Hz,2H),3.45(dt,J＝10.3,6.0Hz,4H),1.97(p,J＝6.2Hz,2H),1.88–1.62(m,4H),1.32(d,J＝6.6Hz,6H).
实施例14
参考实施例1的合成方法，可制得化合物14。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.75–7.61(m,4H),7.48(ddt,J＝7.8,6.4,1.8Hz,4H),7.42–7.31(m,2H),4.97(s,2H),4.48–4.32(m,4H),4.01(s,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.46(t,J＝6.0Hz,2H),1.93–1.63(m,4H),1.32(d,J＝6.6Hz,6H).
实施例15
参考实施例1的合成方法，可制得化合物15。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝11.6,6.2,1.5Hz,4H),7.57–7.42(m,4H),7.42–7.26(m,2H),5.89(s,2H),5.00(s,2H),4.11(s,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.93–1.64(m,4H),1.32(d,J＝6.6Hz,6H).
实施例16
参考实施例1的合成方法，可制得化合物16。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.67(ddt,J＝7.9,6.1,1.4Hz,4H),7.56–7.43(m,4H),7.43–7.27(m,2H),4.62(t,J＝7.1Hz,2H),4.28–4.08(m,6H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.2Hz,2H),3.47(t,J＝6.0Hz,2H),2.78(t,J＝7.1Hz,2H),2.05(p,J＝6.0Hz,2H),1.90–1.62(m,4H),1.32(d,J＝6.6Hz,6H).
实施例17
参考实施例1的合成方法，可制得化合物17。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.72–7.53(m,4H),7.53–7.41(m,6H),7.41–7.21(m,4H),5.41(t,J＝1.0Hz,2H),5.18(s,2H),4.54(t,J＝1.0Hz,2H),4.08(s,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.93–1.59(m,4H),1.33(d,J＝6.5Hz,6H).
实施例18
参考实施例1的合成方法，可制得化合物18。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.63(ddt,J＝19.9,6.2,1.5Hz,4H),7.52–7.41(m,6H),7.41–7.29(m,2H),7.29–7.10(m,2H),5.90(s,2H),5.42(t,J＝0.9Hz,2H),4.20–3.97(m,2H),3.84(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.58(t,J＝1.0Hz,2H),3.47(t,J＝6.0Hz,2H),1.89–1.60(m,4H),1.33(d,J＝6.5Hz,6H).
实施例19
合成方法
将MRE-269(80mg)，氯甲基呋咱氮氧化物和DMAP，TEA用2mL无水二氯甲烷溶解，室温搅拌四小时后，反应液中加入3mL二氯甲烷稀释，依次用10％的盐酸洗两次，饱和食盐水洗一次，过滤，滤液浓缩，HPLC纯化得化合物19，收率60％。
1H NMR(300MHz,Chloroform-d)δ7.95–7.80(m,3H),7.68–7.55(m,5H),7.55–7.42(m,6H),7.42–7.31(m,2H),6.03(s,2H),4.08(s,2H),3.88(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.47(t,J＝6.0Hz,2H),1.95–1.60(m,4H),1.33(d,J＝6.5Hz,6H).
实施例20
参考实施例19的合成方法，可制得化合物20。
1H NMR(300MHz,Chloroform-d)δ7.86(s,1H),7.72–7.43(m,13H),7.43–7.24(m,2H),4.68–4.38(m,4H),4.01(s,2H),3.88(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.46(t,J＝6.0Hz,2H),1.93–1.55(m,4H),1.33(d,J＝6.5Hz,6H).
实施例21
参考实施例19的合成方法，可制得化合物21。
1H NMR(300MHz,Chloroform-d)δ7.92–7.76(m,3H),7.66–7.53(m,5H),7.53–7.42(m,6H),4.38(t,J＝6.1Hz,2H),4.21(t,J＝6.1Hz,2H),4.10(s,2H),3.88(hept,J＝6.5Hz,1H),3.68(t,J＝6.3Hz,2H),3.46(t,J＝6.0Hz,2H),2.15(p,J＝6.1Hz,2H),1.85–1.63(m,4H),1.33(d,J＝6.5Hz,6H).
试验例1
低氧性肺动脉高压大鼠体内试验
(一)实验仪器和材料
HX-200动物呼吸机，实验所用SD雄性大鼠均购自扬州大学，生理盐水。所有对照组在正常环境下饲养，干预组和模型组在低压低氧舱内饲养(气压50kPa，氧浓度10％)。
(二)实验步骤
化合物1使用DMSO/solutol/water(10/10/80)溶解制成澄清溶液，干预组从低氧第二天开始，灌胃给药化合物1剂量5mg/kg，所有大鼠每周称重，记录生存情况，四周后测定肺动脉压力。用水合氯醛(100g/L)麻醉大鼠(3mL/kg)，仰卧位固定，行气管切开，用小动物呼吸机辅助呼吸(频率60次/min，潮气量5mL，吸呼比4:5)。游离左侧第3肋骨，将一端连接张力换能器的导管送至肺动脉，通过BL-420E生物机能实验系统记录平均肺动脉压力(mPAP)。检查并收集胸水、腹水，最后从腹主动脉抽血将大鼠处死。
(三)实验结果
见附图1，与对照组相比，模型组大鼠的mPAP明显升高，给药化合物1的干预组mPAP较模型组降低。
试验例2
化合物的药代动力学实验
(一)实验仪器和材料
高速冷冻离心机，涡旋振荡器(Vortex Genius3)，高速离心机(Eppendorf5415D)，一次性使用注射器，移液枪(Eppendorf)，实验所用SD雄性大鼠均购自扬州大学，EDTA-K2真空采血管，生理盐水。所有口服组大鼠在给药前禁食12h，自由饮水，给药期间自由进水和进食。
(二)实验步骤
本发明的实施例化合物使用DMSO/solutol/water(10/10/80)溶解制成澄清溶液，灌胃给药化合物剂量25mg/kg，尾静脉给药化合物的剂量为5mg/kg。于尾静脉给药后的2min,10min,30min,1h,2h,3h,5h,8h,12h,16h,24h，从眼底静脉丛连续取血0.5mL至肝素管中，灌胃给药后的5min,15min,30min,1h,2h,3h,5h,8h,12h,16h,24h，从眼底静脉丛连续取血0.5mL肝素管中。将样品在8000r，4℃条件下离心10min后，取上层血浆0.15mL，-20℃条件下保存，之后进行LC-MS/MS分析。数据通过WinNolin非房室模型分析，得到关键药代动力学参数。
(三)实验结果
表1化合物的药代动力学参数
由上述试验结果可以发现，相对于司来帕格的达峰时间(1.8h)和半衰期(3h)，本发明的化合物明显延长了达峰时间和半衰期，具有优异的长效给药的潜力及良好的口服给药潜力。
最后应当说明的是，以上内容仅用以说明本发明的技术方案，而非对本发明保护范围的限制，本领域的普通技术人员对本发明的技术方案进行的简单修改或者等同替换，均不脱离本发明技术方案的实质和范围。
Claims (9)
1.一种如式I所示的司来帕格体内代谢物的一氧化氮供体药物：
其中，n为0，1，2，3或4；
R为-X-ONO2、-OC(O)-X-ONO2、-O-X-ONO2、或
其中X为直链或支链的C1-C10亚烷基、C3-7环亚烷基、C6-10芳基、C6-10芳基-C1-C10亚烷基或C1-C10亚烷基-C6-10芳基-C1-C10亚烷基；其中C1-C10亚烷基、C3-7环亚烷基或C6-10芳基可被以下一个或者多个取代基取代：卤原子、羟基、羧基、氰基或-(C1-C10亚烷基)-ONO2。
2.根据权利要求1所述的司来帕格体内代谢物的一氧化氮供体药物，其特征在于：X为直链或支链的C1-C6亚烷基、C4-6环亚烷基、苯基、苯基-C1-C6亚烷基或C1-C6亚烷基-苯基-C1-C6亚烷基；其中C1-C6亚烷基、C4-6环亚烷基或苯基可被以下一个或者多个取代基取代：卤原子、羟基、羧基、氰基或-(C1-C6亚烷基)-ONO2。
3.根据权利要求1所述的司来帕格体内代谢物的一氧化氮供体药物，其特征在于，式I化合物选自如下结构：
4.一种药物组合物，包含权利要求1-3任一项所述的司来帕格体内代谢物的一氧化氮供体药物和药学上可接受的辅料。
5.根据权利要求4所述的药物组合物，其特征在于，所述组合物还包含附加治疗剂，所述附加治疗剂为波生坦、安立生坦和/或西地那非。
6.根据权利要求4或5所述的药物组合物，其特征在于，所述药物组合物为口服剂型。
7.根据权利要求6所述的药物组合物，所述口服剂型包括片剂、胶囊剂、囊片剂、丸剂、含片剂、粉剂、糖浆剂、酏剂、混悬剂、溶液剂、乳剂、颗粒剂或扁囊剂。
8.权利要求1-3任一项所述的司来帕格体内代谢物的一氧化氮供体药物或权利要求4-7任一项所述的药物组合物在制备治疗肺动脉高压的药物中的应用。
9.权利要求1-3任一项所述的司来帕格体内代谢物的一氧化氮供体药物或权利要求4-7任一项所述的药物组合物在制备前列环素受体激动剂中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310167400.0A CN116143704A (zh) | 2023-02-27 | 2023-02-27 | 司来帕格体内代谢物的一氧化氮供体药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310167400.0A CN116143704A (zh) | 2023-02-27 | 2023-02-27 | 司来帕格体内代谢物的一氧化氮供体药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116143704A true CN116143704A (zh) | 2023-05-23 |
Family
ID=86373322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310167400.0A Pending CN116143704A (zh) | 2023-02-27 | 2023-02-27 | 司来帕格体内代谢物的一氧化氮供体药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116143704A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024131672A1 (zh) * | 2022-12-20 | 2024-06-27 | 长风药业股份有限公司 | 二苯基吡嗪类衍生物、其制备方法及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1516690A (zh) * | 2001-04-26 | 2004-07-28 | �ձ���ҩ��ʽ���� | 杂环衍生物及医药品 |
| WO2018019296A1 (zh) * | 2016-07-29 | 2018-02-01 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
| CN113968824A (zh) * | 2021-11-29 | 2022-01-25 | 郑州大学 | 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用 |
-
2023
- 2023-02-27 CN CN202310167400.0A patent/CN116143704A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1516690A (zh) * | 2001-04-26 | 2004-07-28 | �ձ���ҩ��ʽ���� | 杂环衍生物及医药品 |
| WO2018019296A1 (zh) * | 2016-07-29 | 2018-02-01 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
| CN113968824A (zh) * | 2021-11-29 | 2022-01-25 | 郑州大学 | 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024131672A1 (zh) * | 2022-12-20 | 2024-06-27 | 长风药业股份有限公司 | 二苯基吡嗪类衍生物、其制备方法及应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107721958B (zh) | 靶向癌症干细胞的新的化合物和组合物 | |
| EP3002274A1 (en) | Treprostinil monohydrate | |
| US20110124675A1 (en) | The hydrosulfate of prasugrel, its pharmaceutical combination and use thereof | |
| ES2802977T3 (es) | Compuesto para la modulación inmunológica, uso del mismo y composición farmacéutica que lo comprende | |
| JPH0326183B2 (zh) | ||
| CN115960148B (zh) | 一种新型的胞苷衍生物及其药物组合物和用途 | |
| CN116143704A (zh) | 司来帕格体内代谢物的一氧化氮供体药物 | |
| CN115894240B (zh) | 曲前列尼尔的前体药物及其应用 | |
| CN115448839B (zh) | 一种曲前列尼尔的前体药物 | |
| WO2023221825A1 (zh) | 一种倍半萜衍生物、其药物组合物及其制备方法和用途 | |
| JPWO2002020540A1 (ja) | アデノシン誘導体及びその用途 | |
| EP2325187A1 (en) | The hydrosulfate of prasugrel, its pharmaceutical combination and uses thereof | |
| CN114349745B (zh) | 一种用于治疗心肌缺血的药物及其制备方法 | |
| JP2008531516A (ja) | レルカニジピン遊離塩基 | |
| CN116143742B (zh) | 依前列醇一氧化氮供体药物 | |
| CN116178233A (zh) | 伊洛前列素一氧化氮供体药物 | |
| CN106478764B (zh) | 丹参酮iia磷酸衍生物、及其合成和作为药物的应用 | |
| JP2002293745A (ja) | 慢性関節リウマチ治療剤 | |
| WO1995005825A1 (fr) | Traitement symptomatique des troubles circulatoires | |
| CN119613310A (zh) | 一种伊洛前列素衍生物及其制备方法和应用 | |
| US4562206A (en) | Orally effective inotropic compounds | |
| CN116874456A (zh) | 贝前列素的前体药物 | |
| CN104188983A (zh) | 闭花木酮Cleistanone的O-(吗啉基)乙基衍生物在制备抗心衰药物中的应用 | |
| CN118724879B (zh) | 一种氘代稠环化合物及其制备方法与用途 | |
| WO2013083014A1 (zh) | 黄豆苷元衍生物、其药学上可接受的盐、制备方法以及包含其的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |